KRS Capital Management LLC Has $283,000 Stock Position in Johnson & Johnson $JNJ

KRS Capital Management LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 8.9% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,855 shares of the company’s stock after selling 181 shares during the period. KRS Capital Management LLC’s holdings in Johnson & Johnson were worth $283,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of JNJ. Brighton Jones LLC grew its stake in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the last quarter. Wealth Group Ltd. acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $218,000. GAMMA Investing LLC grew its position in shares of Johnson & Johnson by 48.0% during the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock worth $7,215,000 after purchasing an additional 14,118 shares in the last quarter. Dodds Wealth LLC grew its position in shares of Johnson & Johnson by 15.6% during the 1st quarter. Dodds Wealth LLC now owns 3,576 shares of the company’s stock worth $593,000 after purchasing an additional 482 shares in the last quarter. Finally, Founders Grove Wealth Partners LLC grew its position in shares of Johnson & Johnson by 2.5% during the 1st quarter. Founders Grove Wealth Partners LLC now owns 6,886 shares of the company’s stock worth $1,142,000 after purchasing an additional 168 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of analyst reports. JPMorgan Chase & Co. increased their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Sanford C. Bernstein increased their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $192.94.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $190.66 on Friday. The company has a market cap of $459.16 billion, a PE ratio of 20.39, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a 50 day moving average of $178.48 and a 200-day moving average of $163.77. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $192.10.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.